The best MSS Colorectal Cancer Talk and Clinical Trial at ASCO 2017

First of all, sorry that this post has been delayed so much!  Last year I was able to write up my ASCO post with almost no delay but unfortunately this year my personal medical situation intruded (a little thing called trying to save my life with the June 1st Y90-SIRT)!  So here it finally is, delayed by about a month!


What do I think was the biggest MSS colorectal cancer presentation and clinical trial at ASCO 2017?

OK get ready for this.  It is a mouthful.  And scientists & clinicians wonder why patients are intimidated and confused by the clinical trial world???? This is the winner: Abstract #3002.  OK that was the easy part.  Now, the hard part – here is the title: “Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC)”.  I warned you it was intimidating!  If I were to print this post out I think that talk title hyperlink would use up my blue ink!  Like I said, it is no wonder the average patient has trouble figuring out scientific breakthroughs when scientists use language like that in their abstract titles!

But I’m here to help

First of all what did the study show?

The study gave the preliminary results of a Phase 1 clinical trial of a novel new immunotherapy enrolling MSS Colorectal cancer patients called “RO6958688” aka “CEA CD3 TCB” & “RG7802” (how many names does one experimental therapy need??).  RO6958688 was tested in patients by itself (i.e. as a “monotherapy”) as well as in combination with the PDL1 inhibitor (a type of “checkpoint inhibitor“) called “atezolizumab”. It is a moderately large Phase 1 trial that as of the data cut-off for ASCO had been tested in 118 patients (96 of which were MSS-CRC patients).  The trial is: NCT02650713. 

In the monotherapy arm of the trial at doses >60 mg, 16% of patients (and in the combination arm of the trial at doses >60 mg, 70% of patients) saw tumor size reduction of at least 10%.  My personal feeling is that the important goal of trials should be (at least) stable disease, so using that criteria, 45% of patients in the monotherapy arm and 82% of patients in the combination arm of the trial showed at least “stable disease”.  Almost all of the tested patients at these dose levels had MSS-CRC.

This is a previously unheard of level of response to an immunotherapy in MSS-CRC patients!

As has been well publicized, MSS-CRC is resistant towards immunotherapies, although I think too many people throw that phrase around, over simplifying & equating “immunotherapy” with “PD(L)1 inhibitors”.  But it is true, MSS-CRC tumors are intrinsically immunosuppressed in the vast majority of patients, so what was the drug design trick they used to gain such a high response rate with RO6958688?  Brute force.

How does RO6958688 work?

RO6958688 is something called a “bispecific antibody”.  Get used to that term because they are some of the biggest potential breakthroughs coming out of preclinical labs and entering clinical trial assessment right now!

Therapeutic antibodies have been used for years now as drugs.  Within the CRC world, one example is cetuximab (Erbitux) which is a therapeutic antibody which targets the EGFR receptor. As you can guess from the name “Bispecific”, the new generation of antibodies such as RO6958688 target not one protein (like the cetuximab/EGFR example) but instead they target two separate proteins simultaneously.  Although this is a simplification, you can think of RO6958688 as a chain with two ends, each targeting a different protein.

Specifically, RO6958688 targets “CEA (Carcinoembryonic antigen)” on one end and on the other end “CD3” (a protein on immune T-cells).  About 90% of CRC tumors express the CEA protein on their surface.  So the drug binds to the CRC cancer cell surface on one end (via CEA) and binds to an immune cell on the other end (via CD3)… this physically yanks the immune cell by brute force into close proximity to the CRC cancer cell and it then attacks!  It is like a ship dragging immune cells, forcing them up river against an immunosuppressive current trying to keep them out of the tumor.  This brute force technique can overcome many of the tricks that MSS-CRC tumors use to evade the immune system.

Boat Going Against Current

“CEA” is very well known to CRC patients because it is the protein in blood that is used as a blood test to track the course of disease in many patients.  When patients first hear that RO6958688 targets CEA, they often ask two very logical questions: 1.) Doesn’t the CEA in the blood confuse the drug as an unintended target? 2.) Many CRC patients have low CEA measurements in their blood tests, can RO6958688 work in those patients?  The answers are: 1.) The design of the CEA-targeting moiety of RO6958688 is very savvy – it specifically targets a form of CEA that is bound to a cell surface, not CEA free-floating in the blood and 2.) There is not a direct correlation between the amount of CEA expressed by a patient’s tumors and CEA in that patient’s bloodstream – so yes, the drug should be able to work even if a patient has low blood CEA levels. Oftentimes a tumor expresses a lot of CEA – it just isn’t released into the blood allowing it to be measured by the standard CEA blood test!

One concern I had when this experimental therapy & clinical trial was first announced was what its safety profile would be.  CD3 T-Cells are very powerful and although tumors express CEA at higher levels than normal tissues, normal tissues do express some CEA as well, potentially setting up major toxicity. In terms of toxicity profile, RO6958688 has shown a better toxicity profile than I had feared may happen but… for a number of reasons still currently under investigation, it has shown a tight safety window and there has been at least one death on the trial while they continue to figure out the proper dosing and dosing protocols.  As of right now, it appears that there may indeed be a safe dose/dosing path forward but this continues to be an issue that they are working out and thus this should be known by patients.

Sometimes people mistakenly believe that immunotherapies are safer or less toxic than traditional chemotherapy.  This is not automatically the case!  The immune system is very powerful and unleashing it can have toxic consequences if not done properly – but that is precisely what Phase 1 clinical trials are meant to figure out!  The fundamental role of Phase 1 clinical trials is to determine a dose level and dosing protocol with an adequate safety profile to move into Phase 2 clinical trial testing.

So that is where things stand in terms of what I think is the most exciting current clinical trial results for MSS-CRC released so far in 2017, at ASCO or otherwise.  RO6958688, especially when combined with a PD(L)1 inhibitor, is an exciting new experimental therapy!  Clinical investigators are still continuing the Phase 1 trial to further define the best way to dose RO6958688, maximizing efficacy balanced by safety.  They are now spreading to additional trial sites nationwide (Trial: NCT02650713).  An additional piece of data that still needs to be defined is how durable the efficacy is in patients – i.e. how long does it work?  Can tumors evolve around the CEA binding like they can evolve against targeted therapies?  This remains to be defined.

There will be additional tricks found to get around the immunosuppressed nature of MSS-CRC tumors but the bispecific antibody strategy of RO6958688 appears to be one successful trick to add to the MSS-CRC immunotherapy tool box – and for that reason, in my opinion it is the best MSS colorectal cancer talk and clinical trial at ASCO 2017.  Watch this therapy closely as they continue to define its clinical profile!

Progress continues to be made in the immunotherapy attack on MSS colorectal cancer – stay tuned!


12 Comments on “The best MSS Colorectal Cancer Talk and Clinical Trial at ASCO 2017

  1. This should lead to treatment-altering changing for so many people in the CRC community. Thank you for explaining this so carefully.


  2. Thanks for this ASCO update. How long has this trial been going on so far, and therefore what is the longest we have seen the results successful for?


    • I don’t know the exact answer to how long the trial has been going on but it was first uploaded to in Januuary 2016. Keep in mind as a Phase 1 trial, the initial patients were given doses lower than the 60 mg+ dose which appears to be efficacious. In their ASCO slides they showed 3 patients currently on trial at the 24 week mark (with tumor size reduction) – all 3 patients were continuing on trial at that time mark with continued response.


  3. Thank you so much for the explanation of this trial. Thankful for you taking time away from your own recovery and family on this holiday weekend. I just had a trip to er on Wednesday thinking I had a blockage or strangulation of my umbilical hernia. CT showed lymph node in the aortic bilification again and possibly something that used to be my uterus. Stupid that they left it in me in 2010 when I had my first surgery….but took the ovaries and tubes. Pet scan on July 12th and results on the 14th.
    So I am excited about this trial and maybe it will help me if I cannot be surgically cleaned up.
    You may remember that in August 2015 I had a single lymph node recurrence and the cancer had eaten up the attached iliac artery and the surgeon called in a vascular surgeon who cut out the artery up to the aortic verge and placed a graft. However he couldn’t get clean margins on the aortic artery.
    We have been just scanning and waiting for the last 2 years and in March I was moved to every 6 months. So much for that….but hopefully we can get another year with surgery. I have very slow growing type. MSS, APC,CHD1, SMAD4, TP53, WILD TYPE NRAS AND KRAS. I just saw a vascular doctor to see if he could do an aortic replacement….we thought that it might be be proactive to not let the cancer continue to grow up the abdominal aortic artery and just bust open.
    But, we will see how things progress with pet scan and or biopsies.
    I go to Emory Winship Cancer Institute NCI in Atlanta.
    Dr Charles Staley and Dr El-Reyes are currently my medical team so I feel lucky that this trial is for MSS and all I have learned over the last 2 years knowing you and Maia Cee Cee Walker.
    Thank you again for your generous gift of medical and scientific research and sharing your experiences with us.
    Chrissy Rice


  4. Thanks from myself and my whole family! I had to read it twice but you do a terrific job of explaining abstruse matters to those with minimal relevant scientific training. We’re grateful to you for all the edifying you do and the hope that travels along with it.


  5. Do you have any updates on the immunotherapy trial that you mentoned from last years ASCO 2016 conference? They had bumped it up to a phase 3 trial because of initial positive results? Was wondering if that has gone well and if they might be considering FDA approval?


    • They have not released data from the in progress Phase 3 trial yet but it has accrued at a very fast rate – the US trial sites were basically filled up by last Fall. So I think they will be releasing data at a much faster timeline than average.


  6. Thank you Tom for your relevant work in triyng to translate complex medical information into a clearer language in order to help people understand.
    By the way, do you run at the moment ?
    Pascale, Orléans, France


    • Hi Loze, I am not currently running but I miss doing it & I look forward to restarting when my health allows it again! -Tom


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s


Scroll naar beneden langs de grote bomen:-)

My Cancered Life

Relentlessly Attacking Cancer Through Fitness, Family, Advocacy, and Laughter


Přejděte dolů kolem velkých stromů :-)


Más allá de los grandes árboles :-)


向下拖动滚动条看看大树底下 :-)


Пролистайте вниз мимо больших деревьев :-)

Cancer Riot

Scroll Down Past the Big Trees :-)

SugarCone Biotech

Research and Development - Analysis, Consulting, Investment

Fightin 4

Colorectal Cancer Awareness

Tami Boehmer | Miracle Survivors

Just another site

Adventures in Spiritual Living

Riding the spiritual waves of everyday life

life and breath: outliving lung cancer

for the terminally optimistic

%d bloggers like this: